KTE-X19 Continues to Elicit Durable Responses in Relapsed/Refractory MCL
February 24th 2021
February 24, 2021 - The CAR T-cell product KTE-X19 continues to demonstrate durable clinical benefit in patients with relapsed/refractory mantle cell lymphoma, with an overall response rate of 92%.